This week a new study is presented in Sweden suggesting that it may be possible to tether cancer drugs together to make them more effective. A team led by Sara Hurvitz of UCLA created T-DM1 which links Herceptin to a drug called DM-1.
Herceptin, a monoclonal antibody, binds to cells that make too much of a protein called HER-2.
DM-1 targets all cells, but is inactive when linked to Herpcetin. When Herceptin binds to HER-2, however, the DM-1 is released and can act on nearby cancer cells.
The docs are thinking that this might provide a more targeted one-two punch than Herceptin plus Taxotere (also called docetaxel, rather the standard so far.)